What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Immunology And Oncology Pipelines Expanding

Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.

Sanofi
Sanofi's Frank Nestle talked to Scrip about R&D • Source: Shutterstock

Sanofi's approach to drug discovery and early pipeline development has been changing over the last five years, and global head of research and chief scientific officer Frank Nestle said in an interview that some of the investment that has been put in is beginning to deliver promising new drug candidates.

"It's a science-led organization with a cultural drive, with a play-to-win attitude and a portfolio that is evolving but already...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip